Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

NCT05199584 is registered in ClinicalTrials.gov with Endeavor Biomedicines, Inc. as lead sponsor.

NCT NCT05199584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05199584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Lead sponsor
Endeavor Biomedicines, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 24, 2022
Completion date
February 20, 2024
Enrollment
20 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors with ptch1 loss-of-function mutations